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Greater platelet inhibition has been associated with improved angiographic outcomes pre and post percutaneous coronary intervention (PCI). The 
angiographic outcomes were compared in the ticagrelor and clopidogrel arms pre and post PCI.
Methods:  The present cohort is a subset of 1657 PCI patients (pts) with evaluable angiographic data from the 18,624 pts PLATO trial. Clopidogrel 
naïve or pre-treated pts were randomized to 180mg ticagrelor or 300mg clopidogrel. PCI pts were administered, as per treatment group, additional 
90mg ticagrelor if >24hrs after the initial loading dose or an optional further 300mg clopidogrel or placebo (total 600 mg) prior to PCI. The sub-
study primary endpoint was the incidence of post PCI TIMI myocardial perfusion grade 3 (TMPG 3) among patients who received the drug prior to 
PCI. Pre-PCI TMPG, Corrected TIMI frame count (CTFC), TIMI thrombus grade (TTG), TIMI flow grade (TFG), minimum lumen diameter (MLD) and % 
diameter stenosis (DS) were also measured.
Results:  TMPG 3 post PCI was similar between the ticagrelor and clopidogrel groups [Table]. Likewise there was no difference in CTFC (median 78 
vs. 62), TMPG 3 (32.6 vs. 32.5%), TFG 3 (39.9 vs. 40.9%), TTG 0 (26.3 vs. 29.3%), and MLD (Q1-Q3) [0.3 (0.0-0.6) vs. 0.3 (0.0-0.6) mm] and %DS of 
culprit artery [88 (76-100) vs. 88 (76-100)%] prior to PCI between the 2 groups respectively.
Conclusion: In the PLATO angiographic sub-study, the angiographic outcomes including TMPG were similar among patients treated with ticagrelor 
and clopidogrel. 
Overall Ticagrelor Clopidogrel p-valuen(%) n(%) n(%)
N = 1657 N = 841 N = 816
Normal (TMPG 3) 779 (47.0) 396 (47.1) 383 (46.9) 0.9608Abnormal (TMPG 0-2) 878 (53.0) 445 (52.9) 433 (53.1)
In STEMI* patients N = 989 N = 502 N = 487
Normal (TMPG 3) 412 (41.7) 213 (42.4) 199 (40.9) 0.6517Abnormal (TMPG 0-2) 577 (58.3) 289 (57.6) 288 (59.1)
In NSTEMI/UA patients N = 668 N = 339 N = 329
Normal (TMPG 3) 367 (54.9) 183 (54.0) 184 (55.9) 0.6411Abnormal (TMPG 0-2) 301 (45.1) 156 (46.0) 145 (44.1)
p-value for the treatment by type of ACS interaction: 0.4790, * STEMI defined as persistent ST elevation or new LBBB. STEMI- ST elevation 
myocardial infarction, NSTEMI- Non ST elevation myocardial infarction, UA- Unstable angina. 
